Combinations with BCR inhibitors (e.g., acalabrutinib) or HDAC inhibitors (e.g., vorinostat) in R/R DLBCL have also yielded ORRs ranging from 26% to 55%, with enhanced responses observed in patients with PD-L1 expression [73,74]. Here, BCR is linked to diffuse large B-cell lymphoma.